New device could spare colon cancer patients from temporary stoma
NCT ID NCT06540807
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a temporary device called Colovac 2 in 24 people undergoing colon cancer surgery. The device is placed inside the bowel to protect the surgical connection while it heals, potentially avoiding the need for a temporary stoma. Researchers checked if the device stayed in place and was safe over 10 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Colovac 2 colorectal anastomosis protection device
- What this could lead to
- If successful, this device could allow surgeons to avoid creating a temporary stoma in many patients, reducing recovery time and complications.
- What could go wrong
- This is a small, early feasibility study with only 24 participants. The device may not work as intended, and risks like device migration or infection remain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
24 people
The number who actually took part.
- Started
-
Jul 2024
- Finished
-
Dec 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 years of age or older * Eligible to undergo open or minimally invasive sphincter-sparing low anterior resection with planned diverting loop ileostomy for malignancy, based on multidisciplinary team recommendations * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2History of left sided colitis * Willingness to comply with protocol-specific treatment and study visits and to sign a written Informed Consent Form Exclusion Criteria: * History of left sided colitis * Known allergy to nickel or other components of the Colovac 2 System * Pregnant or nursing female subject * Concomitant major surgical procedure in combination with Colorectal resection (i.e., hepatectomy) * Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation, impair the ability of the participant to undergo protocol described procedures or interfere with the interpretation of study results including, but not limited to: * Stage IV colorectal cancer unless curative intent R0 resection is planned AND there is no associated peritoneal disease * Immunodeficiency (CD4+ count \< 500 CU MM) * Systemic steroid therapy within the past 6 months * Systemic infection at the time of surgery or requiring systemic antimicrobial therapy up to 1 week before surgery * Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study * Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, carcinomatosis * Fecal incontinence, involvement of sphincter by the neoplastic disease or evidence of extensive local disease in the pelvis seen on pre-operative imaging * Severe malnutrition which is defined as at least 10% weight loss within 3 months prior to enrollment. * Occurrence of any of the following during the colorectal surgery: 1. Blood loss (\>750 cc) 2. Blood transfusion 3. Any new sign of ischemia 4. Positive air leak test 5. Inadequate bowel preparation 6. Anastomosis location greater than 15 cm from the anal verge 7. Other intra-operative risks that preclude the subject from undergoing the procedure with the investigational device
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colon cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AKFA
Tashkent, Uzbekistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ivosidenib plus mFOLFOXIRI and celecoxib as a treatment for BRAF-targeted therapy-refractory BRAF V600E-mutant colorectal cancer patients: a phase II study
- Can a new drug shrink advanced solid tumors?
- Can a new drug shrink tumors that resist standard care?
- Can a Two-Drug immunotherapy combo shrink MSS colon cancer before surgery?
- A single blood draw to detect five cancers before symptoms appear?
- Can a new drug duo shrink Hard-to-Treat tumors?